BioVex Appoints Dr. Thaddeus Pullano as VP, Quality...( WOBURN Mass. Aug. 15 /- BioVex In...)

WOBURN, Mass., Aug. 15 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Dr. Thaddeus Pullano, 53, as Vice President of Quality Assurance.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070815/NYW022 )

Previously, Dr. Pullano served as the Vice President of Quality Systems for Acambis from 2003 to 2007. In this role, he was responsible for all aspects of Quality Systems, including oversight of vaccine manufacturing and clinical quality assurance. Prior to joining Acambis, Dr. Pullano was responsible for quality assurance at Transkaryotic Therapies as the Company transitioned from R&D to manufacturing operations. He has also held a number of positions in quality assurance at Wyeth Vaccines. Dr. Pullano holds a Ph.D. in Biochemistry from the University of Southern California and a BS in Biochemistry from the State University of New York at Binghamton.

Philip Astley-Sparke, President & CEO of BioVex Inc, said:

"Thad has direct and extensive experience with quality systems supporting the manufacture and release of biologics for clinical trials and commercial sale. He becomes part of the core team dedicated to moving our Woburn manufacturing facility, which will supply Phase III and launch grade material, towards operational status."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

BioVex's lead cancer program, OncoVEX(GM-CSF), is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX(GM-CSF) is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head
'/>"/>

SOURCE BioVex Copyright©2007 PR Newswire.

0 GOOD